The Global Hyperbaric Oxygen Therapy (HBOT) Devices Market share is estimated to be valued at USD 3.80 Bn in 2025 and is expected to reach USD 5.46 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.
To learn more about this report, Download Free Sample
The growing adoption of Hyperbaric Oxygen Therapy (HBOT) devices for various disease indications such as soft tissue injuries, air or gas embolism, and healing chronic wounds is expected to drive the market growth during the forecast period. The global Hyperbaric Oxygen Therapy (HBOT) devices market is expected to witness a steady growth owing to the rising prevalence of chronic wounds, increasing incidence of conditions such as diabetic wounds and infections where HBOT proves to be an effective therapeutic solution. Furthermore, rising awareness about the therapeutic benefits of HBOT and growth in healthcare expenditure are also contributing to the growth of global hyperbaric oxygen therapy (HBOT) devices market demand.
|
Current Event |
Description and its Impact |
|
Regulatory Changes & Reimbursement Policies |
|
|
Clinical Research Breakthroughs |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of product, the Monoplace HBOT devices segment is estimated to contribute the highest share of the market with 43.6% in 2025 owing to their convenience and portability. Monoplace devices only accommodate one patient at a time but offer high flexibility as they can be easily transported and installed wherever needed. This has boosted their popularity for use in homecare settings, rural clinics, and ambulances where space and infrastructure are major constraints. Their compact size allows for point-of-care treatment with minimal setup requirements. Additionally, the self-contained design of monoplace chambers simplifies logistics and increases affordability compared to complex multiplace units. This has accelerated their adoption across emerging markets with limited healthcare budgets. Monoplace chambers are also favored for their individualized approach that offers complete isolation and hyperbaric conditions tailored to a single patient's therapy needs.
A study published June 20, 2024, in Medical Devices: Evidence and Research details a mechanical enhancement in monoplace hyperbaric chambers designed to improve safety and comfort. Researchers from Yonsei University modified the oxygen supply to aim directly at patients and added a cooling mechanism. Tests at 2.0 and 3.0 ATA showed improved gas readings lower CO₂ levels, stabilized humidity, and temperature control measurable through a 3-way repeated measures ANOVA.
In terms of application, the wound healing segment is expected to contribute the highest share of the market with 37.6% in 2025 owing to the growing prevalence of non-healing wounds and increased recognition of HBOT as an effective treatment option. Hyperbaric oxygen therapy (HBOT) devices work by stimulating angiogenesis or formation of new blood vessels to improve blood supply and oxygen delivery at the wound site, which is essential for natural wound healing. It is particularly effective for chronic wounds such as diabetic foot ulcers, pressure sores, and wounds resulting from radiation therapy or transplants. With more people suffering from diabetes, vascular diseases and mobility issues, the incidences of hard-to-heal wounds have risen tremendously creating high demand for hyperbaric oxygen therapy. Studies show HBOT supports antibiotic effectiveness and promotes vascular growth, making it especially effective for diabetic foot ulcers. This method offers hope in reducing amputations and improving patient outcomes. Additionally, recent clinical research has demonstrated HBOT's benefits in accelerating healing of wounds including burns and injuries, further promoting its usage for various traumatic and post-surgical indications.
In December 2024, Bridgeport Hospital reports that diabetic patients with stubborn foot wounds are benefiting from hyperbaric oxygen therapy (HBOT) at its Wound Healing & Hyperbaric Medicine Center. At the hospital patients breathe pure oxygen in a pressurized chamber, increasing tissue oxygenation, fighting infection, and enhancing the healing of chronic ulcers unresponsive to standard care.
In terms of end user, the hospitals segment is expected to contribute the highest share of the market with 41.7% in 2025 as they serve as the primary centers for delivering hyperbaric oxygen therapy. Hospitals have necessary infrastructure for safely operating complex hyperbaric equipment along with round-the-clock availability of trained medical professionals for monitoring patients undergoing pressurized oxygen treatment. This makes them suitable for management of severe and complicated cases typically seen in hospital set ups. Additionally, co-location of HBOT facilities within hospitals provides convenience to in-patients and ensures streamlined administration for multi-therapeutic procedures. The concentration of specialized staff and resources in hospitals also favors centralized service delivery and economies of scale. This has led to higher procurement of HBOT devices by hospitals compared to other end users to effectively meet increasing in-patient and out-patient therapy needs.
In October 2024, Hospital da Luz Lisboa launched its new hyperbaric chamber, enhancing regional access to advanced wound healing and recovery treatments. The sophisticated monoplace unit delivers pressurized oxygen therapy above atmospheric levels—facilitating cellular regeneration and accelerated recovery from chronic wounds, infections, sports injuries, and post-surgical conditions.
To learn more about this report, Download Free Sample
North America’s dominance in the hyperbaric oxygen therapy (HBOT) devices market with a share of 35.8% in 2025 can be attributed to factors such as the strong presence of leading manufacturers, favorable reimbursement policies, rising incidence of chronic wounds, and cardiovascular diseases. Additionally, the growing healthcare expenditure and awareness among physicians and patients have significantly boosted adoption. Key players like Hyperbaric SAC and Sechrist Industries continue to introduce innovative products and expand access to therapy across the region. Clinical studies have demonstrated significant improvements in cognitive function, stroke recovery, traumatic brain injury, and even erectile dysfunction, with some trials showing up to 30% improvement in memory and attention among post-stroke patients. The International Hyperbarics Association (IHA) has featured many of these findings and continues to promote both pure and mild HBOT.
In December 2024, USF Health introduced its state-funded Hyperbaric Oxygen Therapy (HBOT) clinical trial, welcoming its first patient to the new center. Florida House Speaker Paul Renner visited the facility to mark the occasion and highlight the initiative's importance in treating veterans and first responders suffering from traumatic brain injuries (TBI). The trial aims to assess the effectiveness of HBOT in improving cognitive and neurological outcomes.
Asia Pacific exhibits the fastest growth with a share of 28.2% in 2025, led by countries such as China, India, and Japan. This can be explained by the rising geriatric population, improving access to healthcare facilities, increasing healthcare expenditures, and supportive government initiatives to promote indigenous manufacturing. Notable domestic brands such as Yangzhou Jiahe Hyperbaric Oxygen Therapy Chamber Equipment Co. Ltd. are well-positioned to tap opportunities in the high potential yet untapped markets. In January 2025, Fiji unveiled a new hyperbaric oxygen therapy (HBOT) chamber at Pacific Specialist Healthcare (PSH) in Nadi. The chamber aims to support the growing diving tourism sector, especially shark-diving by providing essential treatment for decompression sickness and arterial gas embolism
The U.S. accounted the prominent share in the hyperbaric oxygen therapy (HBOT) devices market, driven by the demand for wound healing treatments, including hyperbaric oxygen therapy (HBOT). Increased disposable income has encouraged consumers to seek advanced medical therapies. In February 2023, Maui Memorial Medical Center in the U.S. launched a wound care clinic offering comprehensive treatment with HBOT for non-healing wounds. This is further adding to the hyperbaric therapy devices market share.
India hyperbaric oxygen therapy (HBOT) devices market witnesses’ significant growth due to factors like a large population with increasing healthcare needs, a thriving medical tourism industry, and growing awareness of HBOT’s benefits. Government support, affordable healthcare options, and advancements in medical technologies also contribute. Notably, India’s rapidly aging population is creating a profound shift in the country’s healthcare and housing landscape. With over 300 million Indians projected to be aged 60+ by 2050, the demand for specialized senior care is rising sharply. One critical area seeing momentum is the adoption of Hyperbaric Oxygen Therapy (HBOT) for managing chronic diabetic wounds, a common complication among the elderly, further boosting the market.
Germany hyperbaric oxygen therapy (HBOT) devices market is supported by government initiatives promoting advanced medical treatments. In January 2023, the German Federal Ministry of Health announced funding for innovative healthcare technologies, which is expected to boost the adoption of HBOT devices in clinical settings. Additionally, Germany is exhibiting latest innovations in oxygen therapy and hyperbaric solutions and showcasing underscored growing global demand for accessible respiratory devices. For instance, in November 2025, Shenyang-based Canta Medical made a strong impression at the MEDICA 2024 exhibition in Germany. The company featured a broad portfolio ranging from portable and stationary oxygen concentrators to both soft and hard hyperbaric chambers. Emphasizing its leadership, Canta Medical engaged international attendees across hospitals, home-care, sports, and beauty segments.
The U.K. hyperbaric oxygen therapy (HBOT) devices market is characterized by a growing emphasis on non-invasive treatment options. In February 2023, the National Health Service (NHS) launched a new initiative to integrate HBOT into standard care practices for chronic wounds, promoting wider use of these devices.
To learn more about this report, Download Free Sample
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | US$ 3.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.3% | 2032 Value Projection: | US$ 5.46 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Fink Engineering, ETC Hyperbaric Chambers, HAUX-LIFE-SUPPORT, Gulf Coast Hyperbarics Inc., HEARMEC, Sechrist Industries, OxyHealth, Perry Baromedical, Hyperbaric Medical Solutions, Hyperbaric Technologies, Airox Technologies, B. Braun Melsungen AG, Medtronic, and Smiths Medical |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Chronic diseases have emerged as one of the major public health challenges in both developed and developing countries. The number of people suffering from diabetes, in particular, has increased exponentially over the past few decades.. Diabetes severely impacts wound healing and several patients struggle with non-healing wounds for prolonged periods. Hyperbaric oxygen therapy has proven to be an effective treatment option for diabetic wounds and other non-healing chronic wounds that are not responding to conventional treatments.
For instance, according to the Medscape, it is estimated 828 million adults (420 women, 408 men) had diabetes in 2022. Where, India (212 million) and China (148 million) accounted for the largest proportions with diabetes, followed by the United States, Pakistan, Indonesia, and Brazil. In the U.S., over USD 300 billion is spent annually on medical costs and lost workdays due to DM. It is estimated that one in three to one in five DM patients will develop a chronic non-healing wound, such as a diabetic foot ulcer (DFU), with a high recurrence rate (40% within one year and 65% within five years).
One of the major opportunities in the global hyperbaric oxygen therapy (HBOT) devices market forecast is the expansion of approved indications for treating various medical conditions using HBOT. Historically, HBOT was primarily used for decompression sickness and carbon monoxide poisoning. However, ongoing research has proven its efficacy for a wider range of soft tissue infections, diabetes, multiple sclerosis, and stroke, among others. Key players are actively collaborating with research institutions and hospitals to conduct large clinical trials to gather clinical evidence for expanding usage of HBOT. With growing acceptance of HBOT as an adjunct or alternative therapy, more insurance companies are likely to provide coverage which will increase accessibility.
The Hyperbaric Oxygen Therapy (HBOT) devices market value is undergoing a pivotal shift—from being a niche adjunct treatment to becoming a frontline modality in complex wound management, oncology support, and neurorehabilitation. This evolution is not driven by traditional reimbursement pull or hospital-based protocol push, but by a growing body of mechanistic and clinical evidence—and crucially, by deployment innovation across outpatient and portable segments.
We are seeing a demand-side inversion in HBOT adoption. Historically dominated by tertiary hospitals, the momentum is now with standalone wound care centers and private clinics, particularly in North America and East Asia. For example, in the United States alone, over 75% of non-healing diabetic foot ulcers now get evaluated for HBOT eligibility within 60 days of onset, up from 43% in 2019 (Source: American Diabetes Association, 2024 clinical update). This is a direct result of cross-disciplinary recognition of HBOT as not just a salvage therapy, but a proactive adjunct in tissue recovery.
From a device innovation standpoint, the market is clearly bifurcating between monoplace units for outpatient high-frequency use and multiplace chambers increasingly retrofitted for ICU-adjacent applications. The clinical pivot toward neurological indications—such as post-stroke recovery and traumatic brain injury—has created new functional requirements like EEG integration, variable pressurization cycles, and AI-based oxygen exposure optimization. Companies not aligning to these shifts (particularly legacy OEMs still focused solely on limb salvage indications) are falling out of the value chain.
Regulatory openness is also expanding. For instance, China’s National Medical Products Administration (NMPA) approved more than 22 new HBOT clinics in 2024, with local governments in Guangdong and Jiangsu provinces offering subsidies to install hybrid HBOT and physiotherapy setups in secondary hospitals. This signals state-level strategic interest in HBOT infrastructure for chronic illness management.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
